We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.51%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$791M
AUM Growth
-$79M
Cap. Flow
-$79.2M
Cap. Flow %
-10.01%
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$15.4M
2
LLY icon
Eli Lilly
LLY
+$12.5M
3
EHC icon
Encompass Health
EHC
+$11.3M
4
CAH icon
Cardinal Health
CAH
+$8.16M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.81M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$19.8M
2
UNH icon
UnitedHealth
UNH
+$18M
3
PRCT icon
Procept Biorobotics
PRCT
+$14.6M
4
MOH icon
Molina Healthcare
MOH
+$14.4M
5
MCK icon
McKesson
MCK
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.08T
$45.1M 5.7%
57,870
+16,120
+39% +$12.5M
BSX icon
2
Boston Scientific
BSX
$68.4B
$31.8M 4.02%
296,000
-4,000
-1% -$405K
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$27.4M 3.46%
61,455
-5,295
-8% -$2.44M
GKOS icon
4
Glaukos
GKOS
$9.49B
$24.3M 3.07%
235,000
-35,000
-13% -$3.28M
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$24.1M 3.05%
44,350
-7,150
-14% -$3.74M
THC icon
6
Tenet Healthcare
THC
$22.2B
$24M 3.04%
136,429
+9,729
+8% +$1.46M
DHR icon
7
Danaher
DHR
$138B
$24M 3.03%
121,452
+79,500
+190% +$15.4M
CVS icon
8
CVS Health
CVS
$135B
$20.4M 2.58%
295,362
+59,500
+25% +$3.9M
MCK icon
9
McKesson
MCK
$104B
$20.3M 2.57%
27,717
-19,500
-41% -$13.8M
NBIX icon
10
Neurocrine Biosciences
NBIX
$18.2B
$18.8M 2.37%
149,217
+59,400
+66% +$6.81M
GILD icon
11
Gilead Sciences
GILD
$165B
$18.6M 2.36%
168,150
-65,350
-28% -$6.95M
EXAS
12
DELISTED
Exact Sciences
EXAS
$18.6M 2.35%
350,000
-90,000
-20% -$4.57M
ALHC icon
13
Alignment Healthcare
ALHC
$3.78B
$18M 2.28%
1,287,284
-50,000
-4% -$805K
INSM icon
14
Insmed
INSM
$22.4B
$17.7M 2.23%
175,435
-10,065
-5% -$770K
ELV icon
15
Elevance Health
ELV
$81.5B
$17.4M 2.2%
44,650
-4,300
-9% -$1.73M
EHC icon
16
Encompass Health
EHC
$11.3B
$16.7M 2.11%
136,400
+99,000
+265% +$11.3M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$38.3B
$16.7M 2.11%
51,197
+3,000
+6% +$830K
MDT icon
18
Medtronic
MDT
$112B
$15.6M 1.98%
179,500
-75,500
-30% -$6.4M
COR icon
19
Cencora
COR
$62B
$14.8M 1.87%
49,375
+17,000
+53% +$4.9M
REGN icon
20
Regeneron Pharmaceuticals
REGN
$72.9B
$14.5M 1.84%
27,700
-4,050
-13% -$2.26M
PODD icon
21
Insulet
PODD
$11.8B
$14.5M 1.83%
46,000
-15,000
-25% -$4.33M
DXCM icon
22
DexCom
DXCM
$29B
$13.9M 1.76%
159,500
+4,500
+3% +$353K
ABBV icon
23
AbbVie
ABBV
$465B
$12.9M 1.63%
69,375
-19,275
-22% -$3.58M
ALGN icon
24
Align Technology
ALGN
$12.9B
$12.6M 1.59%
66,500
+25,000
+60% +$4.42M
RPRX icon
25
Royalty Pharma
RPRX
$26.2B
$12.4M 1.57%
344,000
-67,000
-16% -$2.22M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BWS
Buck Wealth Strategies Denver, Colorado $810M AUM 10.81% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
BDWCC
B&D White Capital Company Lakeway, Texas $809M AUM 19.33% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rhenman & Partners Asset Management held 105 positions worth $791M, down 9.1% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $79.2M in Q2 2025, closing 15 positions and reducing 37 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cardinal Health worth $9.24M.

  • Rhenman & Partners Asset Management's largest Q2 2025 buy was Cardinal Health: 55,000 shares worth $9.24M.
  • Rhenman & Partners Asset Management added most to Danaher in Q2 2025, an estimated $15.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $18M.
  • Rhenman & Partners Asset Management fully exited Bristol-Myers Squibb in Q2 2025, selling an estimated $19.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 33% of its $791M portfolio in Q2 2025.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 15 in Q2 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 9.1% quarter-over-quarter to $791M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.